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Abstract
MicroRNAs (miRNAs) are emerging as central players in shaping the biology of the Tumor Microenvironment (TME).
They do so both by modulating their expression levels within the different cells of the TME and by being shuttled
among different cell populations within exosomes and other extracellular vesicles. This review focuses on the
state-of-the-art knowledge of the role of miRNAs in the complexity of the TME and highlights limitations and
challenges in the field. A better understanding of the mechanisms of action of these fascinating micro molecules
will lead to the development of new therapeutic weapons and most importantly, to an improvement in the clinical
outcome of cancer patients.
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Background
While cancer treatment and survival have improved
worldwide, the need for further understanding of the
underlying tumor biology remains. In recent years, there
has been a significant shift in scientific focus towards
the role of the tumor microenvironment (TME) on the
development, growth, and metastatic spread of malig-
nancies. The TME is defined as the surrounding cellular
environment enmeshed around the tumor cells including
endothelial cells, lymphocytes, macrophages, NK cells,
other cells of the immune system, fibroblasts, mesenchy-
mal stem cells (MSCs), and the extracellular matrix
(ECM). Each of these components interacts with and in-
fluences the tumor cells, continually shifting the balance
between pro- and anti-tumor phenotype. One of the pre-
dominant methods of communication between these
cells is through extracellular vesicles and their micro-
RNA (miRNA) cargo. Extracellular vesicles (EVs) are
between 30 nm to a few microns in diameter, are sur-
rounded by a phospholipid bilayer membrane, and are
released from a variety of cell types into the local envir-
onment. There are three well characterized groups of
EVs: 1) exosomes, typically 30–100 nm, 2) microvesicles
(or ectosomes), typically 100–1000 nm, and 3) large
oncosomes, typically 1–10 μm. Each of these categories
has a distinctly unique biogenesis and purpose in cell-
cell communication despite the fact that current labora-
tory methods do not always allow precise differentiation.
EVs are found to be enriched with membrane-bound
proteins, lipid raft-associated and cytosolic proteins,
lipids, DNA, mRNAs, and miRNAs, all of which can be
transferred to the recipient cell upon fusion to allow
cell-cell communications [1]. Of these, miRNAs have
been of particular interest in cancer research, both as
modifiers of transcription and translation as well as dir-
ect inhibitors or enhancers of key regulatory proteins.
These miRNAs are a large family of small non-coding
RNAs (19–24 nucleotides) and are known to be aber-
rantly expressed, both in terms of content as well as
number, in both the tumor cells and the cells of the
TME. Synthesis of these mature miRNA is a complex
process, starting with the transcription of long, capped,
and polyadenylated pri-miRNA by RNA polymerase II.
These are cropped into a 60–100 nucleotide hairpin-
structure pre-miRNA by the microprocessor, a heterodi-
mer of Drosha (a ribonuclease III enzyme) and DGCR8
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(DiGeorge syndrome critical region gene 8). The pre-
miRNA is then exported to the cytoplasm by exportin 5,
cleaved by Dicer, and separated into single strands by
helicases. The now mature miRNA are incorporated into
the RNA-induced silencing complex (RISC), a cytoplas-
mic effector machine of the miRNA pathway. The pri-
mary mechanism of action of the mature miRNA-RISC
complex is through their binding to the 3’ untranslated
region, or less commonly the 5’ untranslated region, of
target mRNA, leading to protein downregulation either
via translational repression or mRNA degradation. More
recently, it has been shown that miRNAs can also up-
regulate the expression of target genes [2]. MiRNA genes
are mostly inter-genic and are transcribed by independ-
ent promoters [3] but can also be encoded by introns,
sharing the same promoter of their host gene [4]. MiR-
NAs undergo the same regulatory mechanisms of any
other protein coding gene (promoter methylation,
histone modifications, etc.…) [5, 6]. Interestingly, each
miRNA may have contradictory effects both within vary-
ing tumor cell lines and within different cells of the
TME. In this review, we provide a state-of-the-art de-
scription of the key role that miRNAs have in the com-
munication between tumor cells and the TME and their
subsequent effects on the malignant phenotype. Finally,
this review has made every effort to clarify, whenever
possible, whether the reference is to the −3p or the -5p
miRNA. Whenever such clarification has not been
provided, this indicates that it was not possible to infer
such information from the cited bibliography.
Angiogenesis and miRNAs
Cellular plasticity, critical in the development of malig-
nancy, includes the many diverse mechanisms elicited by
cancer cells to increase their malignant potential and
develop increasing treatment resistance. One such
mechanism, angiogenesis, is critical to the development
of metastatic disease, affecting both the growth of malig-
nant cells locally and their survival at distant sites. In
the last ten years, miRNAs, often packaged in tumor
cell-derived exosomes, have emerged as important con-
tributors to the complicated regulation and balance of
pro- and anti-angiogenic factors.
Most commonly, miRNAs derived from cancer cells
have oncogenic activity, promoting angiogenesis and
tumor growth and survival. The most-well characterized
of the pro-angiogenic miRNAs, the miR-17-92 cluster
encoding six miRNAs (miR-17, −18a, −19a, −19b, −20a,
and −92a), is found on chromosome 13, and is highly
conserved among vertebrates [7]. The complex and
multifaceted functions of the miR-17-92 cluster are sum-
marized in Fig. 1. Amplification, both at the genetic and
RNA level, of miR-17-92 was initially found in several
lymphoma cell lines and has subsequently been observed
in multiple mouse tumor models [7]. Up-regulation of
this particular locus has further been confirmed in
Fig. 1 Central role of the miR-17-92 cluster in the biology of the TME. The miR-17-92 cluster encoding miR-17, −18a, −19b, −20a, and -92a is upregulated
in multiple tumor types and interacts with various components of the TME to finely “tune” the TME through a complex combination of
pro- and anti-tumoral effects
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miRnome analysis across multiple different tumor types,
including lung, breast, stomach, prostate, colon, and
pancreatic cancer [8]. The miR-17-92 cluster is directly ac-
tivated by Myc and modulates a variety of downstream
transcription factors important in cell cycle regulation
and apoptosis including activation of E2F family and
Cyclin-dependent kinase inhibitor (CDKN1A) and down-
regulation of BCL2L11/BIM and p21 [7]. In addition to
promoting cell cycle progression and inhibiting apop-
tosis, the miR-17-92 cluster also downregulates
thrombospondin-1 (Tsp1) and connective tissue growth
factor (CTGF), important antiangiogenic proteins [7].
Similarly, microvesicles from colorectal cancer cells
contain miR-1246 and TGF-β which are transferred to
endothelial cells to silence promyelocytic leukemia pro-
tein (PML) and activate Smad 1/5/8 signaling promot-
ing proliferation and migration [9]. Likewise, lung
cancer cell line derived microvesicles contain miR-494,
in response to hypoxia, which targets PTEN in the
endothelial cells promoting angiogenesis through the
Akt/eNOS pathway [10]. Lastly, exosomal miR-135b
from multiple myeloma cells suppresses the HIF-1/
FIH-1 pathway in endothelial cells, increasing angio-
genesis [11]. A summary of the studies showing the
functions of exosomal miRNAs in shaping the biology
of the TME is provided in Table 1.
The most common target of anti-angiogenic therapy is
VEGF, and not unsurprisingly, multiple miRNAs (includ-
ing miR-9, miR-20b, miR-130, miR-150, and miR-497)
promote angiogenesis through the induction of the
VEGF pathway. The most studied of these is the up-
regulation of miR-9 which has been linked to a poor
prognosis in multiple tumor types, including breast
cancer, non-small cell lung cancer, and melanoma [12].
The two oncogenes MYC and MYCN activate miR-9
and cause E-cadherin downregulation resulting in the
upregulated transcription of VEGF [13]. In addition,
miR-9 has been shown to upregulate the JAK-STAT
pathway, supporting endothelial cell migration and
tumor angiogenesis [13]. Both amplification of miR-20b
and miR-130 as well as miR-497 suppression regulate
VEGF through hypoxia inducible factor 1α (HIF-1α)
supporting increased angiogenesis [14–17]. Similarly,
miR-146a suppression as often seen in hepatocellular
carcinoma (HCC), leads to increased VEGF expression
through downregulation of APC and upregulation of
HAb18G, thereby portending a poor prognosis [18].
Two further miRNAs promoting angiogenesis are simi-
larly induced by the hypoxic TME. The first, miR-210 is
an important mediator of the endothelial cell response
to low oxygen tension, down-regulating normoxic genes
and activating MYC to stimulate cell cycle progression
[19]. Studies on various primary tumors types have
shown that elevated circulating miR-210 levels are both
a potential diagnostic tool as well as a poor prognostic
indicator at diagnosis [19, 20]. Similarly, hypoxia induces
miR-424 expression in endothelial cells, which targets
cullin 2 (CUL2), a scaffolding protein essential to the
Table 1 Actions of exosomal miRNAs exchanged between cells of the TME
Angiogenesis:
miRNA Cell of origin Accepting cell Pathway/target Effect on TME Ref.
miR-135b Multiple myeloma Endothelial cells HIF-1/FIH-1 ↑angiogenesis [11]
miR-494 Lung cancer Endothelial cells PTEN/AKT/eNOS ↑angiogenesis [10]
miR-503 Endothelial cells Breast cancer Cyclin D2 and D3 ↓Tumor growth and invasion [22]
miR-1246 Colorectal cancer Endothelial Cells PML/Smad 1/5/8 ↑ Growth & migration [9]
Stromal compartment:
miR-105 Breast cancer Endothelial cells ZO-1 ↓Tight junctions
↑Metastatic progression
[68]
miR-202-3p CLL Stromal cells c-fos/ATM ↑Tumor growth [53]
Immune system:
miR-29a NSCLC TAM TLR8/NF-κB ↑Growth & metastasis [75]
miR-21 NSCLC TAM TLR8/NF-κB ↑Growth & metastasis [75]
NBL TAM TLR8/NF-κB ↑miR-155 [76]
miR-155 TAM NBL TERF1 ↑ Drug resistance [76]
miR-23a Hypoxic tumor derived NK cells CD107a ↓ NK cell response [95]
miR-210
miR-214 Tumor cells (various) Regulatory T cells PTEN ↑Immunosuppression [96]
miR-223 TAM Breast cancer Mef2c/β-catenin ↑ Invasion [82]
Abbreviations: TAMs Tumor Associated Macrophages, CLL chronic lymphocytic leukemia, NSCLC non-small cell lung cancer, NBL Neuroblastoma
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ubiquitin ligase system, thus increasing HIF-α levels [21].
While much of the literature has focused on the effect of
cancer cells on the endothelium, there is also emerging
evidence that miRNAs can be transferred to the cancer
cells from the endothelium. One such miRNA, miR-503 is
released in endothelial exosomes and upon uptake by the
breast cancer cells limits tumor growth and invasion by
inhibiting Cyclin D2 and D3 [22].
While many miRNAs provide a pro-angiogenic advan-
tage to the malignant cells, in certain environments,
miRNAs have also been found to be tumor suppressors.
The most well-known anti-angiogenic miRNA is the
miR-200 family which inhibits angiogenesis by targeting
interleukin-8 and CXCL1 [23]. With enhanced delivery
of miR-200 into the tumor endothelium of multiple can-
cer models including ovarian, lung, renal and basal-like
breast cancers, a significant reduction in metastasis for-
mation and angiogenesis was noticed [23]. Similarly,
miR-98 expression downregulates activin receptor-like
kinase-4 (ALK4) and metalloproteinase-11 (MMP11)
expression, and miR-506 downregulates Sphingosine
kinase 1 (SPHK1), thereby inhibiting cell growth and
angiogenesis in breast cancer and hepatoma cell models,
respectively [24, 25]. Additionally, miR-126 regulates
endothelial cell recruitment and vessel formation
through inhibition of Insulin-like growth factor binding
protein 2 (IGFBP2) and c-Mer tyrosine kinase (MERTK)
signaling [26]. Low expression of miR-126 has been
correlated to increased microvessel density and worse
disease prognosis in multiple cancer types including
non-small cell lung cancer, glioblastoma, breast cancer,
and gastric cancer [27]. Lastly, miR-542-3p has been
found to inhibit translation of Angiopoietin-2 mRNA, a
potent hypoxia-induced regulator of endothelial cell
proliferation and migration [28]. Elevated levels of miR-
542-3p cause attenuated endothelial cell angiogenesis
in culture and reduced tumor burden in mouse models
[28]. Clinical prognosis in patients with Stage III/IV
breast carcinoma is inversely correlated with miR-542-
3p levels [28].
Stroma and miRNAs
Angiogenesis is essential to the development of tumor
growth and metastatic disease, however, without the
stroma, the tumor cells would be unable to establish a
favorable niche. Fibroblasts, the predominant cellular
feature of stroma, are responsible for the formation and
maintenance of the extracellular matrix. Additionally,
stromal cells, including fibroblasts, perivascular cells,
and mesenchymal stem cells, generate growth factors to
assist in tumor growth and progression, provide a source
of matrix-remodeling proteins, and influence tumor
angiogenesis [29]. Recent discoveries have found that
tumor-derived exosomes modify the cellular phenotype
of fibroblasts to Cancer-Associated Fibroblasts (CAF).
CAFs have higher expression of α-smooth muscle actin
and secrete a combination of increased growth factors to
promote local epithelial cell growth, increased extracel-
lular matrix (ECM) degrading proteases facilitating ECM
turnover and changes in composition, and increased
modulation of the immune response after tissue injury
[30]. This change in phenotype promotes the growth, in-
vasion, and metastatic potential of the tumor cells and is
a critical step in the progression of malignancy. In
addition to transitioning the fibroblasts to CAFs, miR-
NAs can trigger the molecular process leading epithelial
cells to become phenotypically mesenchymal cells; this
phenomenon is known as the epithelial-mesenchymal
transition (EMT) [31].
The pivotal discovery in 2012 by Mitra et al. laid the
ground-work for our current knowledge on the interac-
tions between tumor-derived miRNAs and fibroblasts. In
combination, the down-regulation of miR-214 and miR-
31 and the up-regulation of miR-155 trigger the repro-
gramming of quiescent fibroblasts to CAFs [32]. As
expected, the reverse regulation of these miRNAs re-
duced the migration and invasion of co-cultured ovarian
cancer cells [32]. While the pathway of miR-155’s in-
volvement in CAF biology is still being elucidated, the
pathways of miR-214 and miR-31 have been established.
In endometrial cancer, miR-31 was found to target the
homeobox gene SATB2, leading to enhanced tumor cell
migration and invasion [33]. MiR-214 similarly has an
inverse correlation with its chemokine target, C-C motif
Ligand 5 (CCL5) [32]. CCL5 secretion has been associ-
ated with enhanced motility, invasion, and metastatic
potential through NF-κB-mediated MMP9 activation
and through generation and differentiation of myeloid-
derived suppressor cells (MDSCs) [34–36]. Furthermore,
miR-210 and miR-133b overexpression and miR-149
suppression have been subsequently found to independ-
ently trigger the conversion to CAFs, possibly through
paracrine stimulation, and to additionally promote EMT
in prostate and gastric cancer, respectively [37–39].
MiR-210 additionally enlists monocytes and encourages
angiogenesis [37]. Similarly, miR-409-3p/-5p overexpres-
sion has also been shown in prostate cancer to induce
the EMT, promote cell growth, and repress tumor sup-
pressors, notably RSU1 and STAG2 [40]. Lastly, in
addition to promotion of angiogenesis as noted above,
the miR-200 family is overexpressed in many solid
tumor cell lines, particularly breast cancer, and is se-
creted into extracellular vesicles to act as an important
regulator of the EMT [41].
Once the fibroblasts have been switched to the CAF
phenotype, they serve two important roles in the TME.
First, they secrete increased growth factors, including
hepatocyte growth factor (HGF), insulin-like growth
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factor (IGF), nerve growth factor (NGF), WNT1, EGF,
FGF2, VEGF, and PDGF [42]. These growth factors pro-
mote cancer cell growth and are critical to the cross-talk
between epithelial cells and fibroblasts. One of the first
miRNA clusters studied in CAFs was the miR-15a/16-1
cluster which is notably down-regulated in CAFs in pa-
tient samples of prostate cancer [43]. Decreased levels of
these two miRNAs led to decreased post-transcriptional
repression of FGF-2 and FGFR-1 causing enhanced can-
cer cell survival [43]. Further work has shown that miR-
15a and miR-16-1 act as tumor suppressors and when
decreased lead to increased levels of BCL2, CCNDI, and
WNT3A in prostate cancer, increased BCL2 in Chronic
Lymphocytic Leukemia, and increased IGSF4 in
leukemia [44–46]. Similarly, miR-148a has been shown
to be down-regulated in endometrial cancer CAFs with
direct upregulation of WNT10B leading to increased
cancer cell motility [47]. Previous work elucidating
miRNA transcriptomes of various tumor types had
shown down-regulation of miR-148a to be part of the
miRNA signature of tumors with increased metastatic
potential [48]. Additionally, miR-21 up-regulation occurs
predominantly in CAFs in breast, lung, colon, and
esophageal cancers and has been shown to contribute to
inducing the CAF phenotype and increase the invasive-
ness and migration of the associated tumor cells [49].
Similarly, miR-101 is notably down-regulated in CAFs
causing increased expression of CXCL12 affecting
migration and invasiveness of lung cancer cells [50].
Additionally, repression of PTEN expression in CAFs
leads to down-regulation of miR-320 and up-regulation
of its oncogene target ETS2, inducing a pro-oncogenic
environment [51]. While low miR-126 expression has
been shown to cause increased angiogenesis as noted
previously, low miR-126 expression has also been shown
to correlate with poor metastasis-free survival of breast
cancer patients due to stromal cell recruitment [52].
Suppressed miR-126/126* levels lead to an increased
levels of both SDF-1α and CCL2 thereby promoting
tumor cell proliferation and recruitment of MSCs and
inflammatory monocytes in the TME [52]. Lastly, Chronic
Lymphoblastic Leukemia (CLL)-derived exosomes are
enriched with miR-202-3p, which when transferred to the
stromal cells, increases c-fos and ATM levels as well as
affects cellular Sufu levels leading to increased tumor
proliferation [53].
Another function of CAFs is the destruction of the
ECM and its remodeling with a tumor-supportive com-
position and structure which includes modulation of
specific integrins and metalloproteinases as some of the
most studied miRNA targets. The 23 matrix metallopro-
teinases (MMPs) are critical in the ECM degradation,
disruption of the growth signal balance, resistance to
apoptosis, establishment of a favorable metastatic niche,
and promotion of angiogenesis [54]. As expected, miR-
NAs have been found to regulate the actions of MMPs,
together working to promote cancer cell growth, inva-
siveness, and metastasis. In HCC, MMP2 and 9 expres-
sion is up-regulated by miR-21 via PTEN pathway
downregulation. Similarly, in cholangiocarcinoma it was
observed that reduced levels of miR-138 induced up-
regulation of RhoC, leading to increased levels of the
same two MMPs [55, 56]. Conversely, miR-29b sup-
presses MMP2 and 9, thus loss of miR-29b expression as
seen in breast cancer, causes increased MMP2 and 9
[57]. Similarly, placental growth factor (PLGF) sup-
presses miR-543 and miR-543 which inhibits MMP7
translation, therefore high levels of PLGF as seen in
ovarian cancer specimens increase MMP7 levels and
thus the cancer’s invasion ability [58]. Likewise, MMP2
and MMP11, in addition to pErk and ADAM15, are up-
regulated due to miR-24’s modulation of the EGFR path-
way [59]. Working in concert, elevated levels of miR-21
additionally have been shown to cause downregulation
of MMP inhibitors RECK and TIMP3 in gliomas and el-
evated miR-24 down-regulates TIMP2 in breast cancer
models, increasing the tumor cells migratory and inva-
sive capabilities [59, 60]. In addition to MMPs, integrins,
heterodimeric receptors responsible for anchoring cells
to ECM proteins and for signal transduction, are simi-
larly vital to the TME. Several miRNAs have been found
in multiple tumor models to target integrins including
miR-93 suppression of integrin-β8, miR-183, miR-124,
and miR-29b suppression of integrin-β1, and miR-29b
suppression of integrin-α6 [57, 61–63]. Lastly, miRNAs
have also been found to directly affect the expression of
stromal components. The presence of miR-17 represses
the expression of both fibronectin and fibronectin type-
III domain containing 3A (FNDC3A) which decreases
cell adhesion and migration [64]. In HCC, miR let-7 g is
inversely correlated with Type 1 collagen α2 levels and
low miR let-7 g levels are directly correlated with poor
survival [65]. Similarly, decreased let-7d in Renal Cell
Carcinoma is associated with advanced tumor stage and
increased vascular invasion secondary to Collagen Type
III α1 and CCL7 activation [66]. In addition, miR-26b,
commonly down-regulated in CAFs, enhances Type XII
Collagen α1 production stimulating epithelial invasion in
breast cancer [67]. Lastly, metastatic breast cancer cells
secrete miR-105 in exosomes which targets tight junc-
tion protein ZO-1 in endothelial cells promoting meta-
static progression [68].
Immune system activation and miRNAs
In addition to the hallmarks of promoting angiogenesis
and a favorable stromal environment for growth and
metastasis, miRNAs also play a critical role in shaping
an inflammatory TME. Infiltrating immune system cells
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can operate both as pro- and anti-tumoral components of
the TME [69]. In recent years, the presence of increased
inflammatory cell infiltration, particularly Tumor Associ-
ated Macrophages (TAMs), has been linked to worse
disease prognosis in most tumor types [70, 71].
TAMs are macrophages, derived predominantly from
bone marrow monocytes, which are recruited by TME-
derived CCL2 to infiltrate tumor tissues [72]. Within the
TME, TAMs are educated by the surrounding tumor
cells and can either adopt the M1-polarized phenotype
which produces pro-inflammatory, antitumor cytokines
(including IL-12 and IL-23), or the M2-polarized pheno-
type which is immunosuppressive and critical in tissue
repair [73]. Particularly in advanced cancers, TAMs are
more frequently educated to the M2-polarized pheno-
type, creating an immunosuppressive environment and
thereby stimulating tumor progression and metastasis
[73]. However, heterogeneity of TAMs within the TME
has been increasingly demonstrated with the presence of
M1-polarized macrophages found in many tumors, par-
ticularly early stage and regressing tumors [74]. The first
complete demonstration of the cross-talk communica-
tion of miRNAs between the TAMs and tumor cells was
shown in lung cancer. Non-small cell lung cancer cells
were shown to secrete miR-21 and miR-29a in exosomes.
These two miRNAs are then taken up by surrounding
TAMs in the TME and bind to Toll-like receptor 8
(TLR8) located inside the TAM’s endosomes. This work
provides the first demonstration of the existence of miR-
ceptors, defined as proteic receptors for miRNAs, whose
signaling is triggered by their binding to specific miRNAs,
in a ligand-receptor fashion [75]. As a consequence of
exosomic miR-21 and miR-29a binding to TLR8, TAMs
secrete increased IL-6 and TNF-α, creating a sterile
inflammatory TME that promotes cancer growth and
dissemination. More recently, the implications of this
mechanism were extended to Neuroblastoma and other
malignancies, where it was shown that cancer cell derived
exosomic miR-21, by binding to TLR8 in surrounding
TAMs, up-regulated the levels of miR-155 in TAMs and
TAM-derived exosomes which were then transferred back
to the cancer cells where the telomerase inhibitor TERF1
was silenced. Silencing of TERF1 led to increased Cis-
platin resistance in both in vitro and in vivo xenografts [8,
76–80]. Increased levels of miR-21 in body fluids and bi-
opsies has been extensively reported as a prognostic and
predictive-of-response-to-treatment marker for several
types of cancers [81]. A similar mechanism showed M2
TAM-derived exosomes containing miR-223 are delivered
to breast cancer cells and promote invasiveness [82]. The
breast cancer cell invasiveness was successfully reversed
when antisense miR-223 was transfected into the tumor
cells [82]. Additionally, TAMs secrete CCL18 which re-
duces miR-98 and miR-27b expression via the Ras/ERK/
PI3K/AKT/NFκB/Lin28b signaling pathway in tumor
cells, thereby enhancing the epithelial-mesenchymal tran-
sition and metastasis of breast cancer cells [83]. Further-
more, miRNAs have been shown to directly affect the
number of infiltrating TAMs in the case of miR-92a
suppression in breast cancer and the protection against
apoptosis of tumor-promoting M2-phenotype TAMs as
evidence by miR-142-3p downregulation in glioblastoma,
both correlating with overall survival [84, 85]. Similarly,
IL-6 released from the tumor cells induce miR-17 and
miR-20a down-regulation in TAMs which induces HIF-2α
and transcription of proangiogenic genes [86]. Lastly,
TAMs with suppression of miR-146a and miR-222 dem-
onstrate promotion of M2-type polarization and macro-
phage chemotaxis in breast cancer models, respectively
[87]. While some TAM-derived miRNAs increase the
growth and invasive potential of the tumor cells, miR-
125b has been show to promote macrophage activation,
exemplified by increased T cell activation, increased sensi-
tivity to IFN-γ, and more effective tumor cell killing [88].
Down-regulation of miR-125b has been described in many
solid tumors, including melanoma, squamous cell carcin-
omas of the mouth and tongue, as well as ovarian, breast,
and prostate cancers [88]. Similarly, miR-23a/27a/24-2
cluster regulates M1- and M2- polarization through a
negative feedback loop [89]. This miRNA cluster has been
shown to be downregulated in the TAMs of breast can-
cer patients, thereby promoting tumor cell growth [89].
Alternatively, miR-511-3p triggers a negative-feedback
response to upregulation of MRC1 during differenti-
ation of pro-tumoral TAMs, mitigating the TAMs pro-
tumoral potential [90].
While TAMs are at the moment the most widely-studied
inflammatory components of the TME, miRNAs also play
a role in the biology of NK cells and T lymphocytes. Pre-
dominantly, miRNAs function to shift the local inflamma-
tory TME to be immunosuppressive and immune tolerant,
allowing cancer cells to grow and metastasize, escaping
immune surveillance. Tumor-derived TGF-β induces miR-
183 in NK cells thereby suppressing DAP12 transcription,
a necessary protein in NK-mediated tumor cell death [91].
Consistent with these findings, lower levels of DAP12 were
observed in the tumor-infiltrating NK cells of multiple lung
cancer subtypes. Working in concert, miR-146a overex-
pression secondary to constitutive STAT3 expression in
HCC, suppresses anti-tumor response by NK cells and
cytotoxic T lymphocytes through increased inflammatory
cytokines and TGF-β, leading to increased cell growth [92].
Similarly, miR-92a is released from glioma cells and
induces NK cell expression of IL-6 and IL-10, significantly
attenuating the expression of NK cell-derived anti-tumor
molecules, including perforin, Fas ligand, and IFN-γ [93].
Furthermore, miR-210 has also been shown to silence
PTPN1, HOXA1, and TP53I11 transcription, decreasing
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the tumor’s susceptibility to Cytotoxic T-lymphocyte killing
[94]. Moreover, miR-23a in addition to miR-210 and TGF-
β, occur in high concentrations in hypoxic tumor-derived
microvesicles with miR-23a directly targeting CD107a ex-
pression in NK cells, decreasing the NK cell response [95].
Lastly, increased secretion of miR-214 in microvesicles
from various human cancers leads to downregulated PTEN
in the regulatory T cells promoting Treg expansion and
enhanced immunosuppression in the TME [96]. While
miRNA can alter NK cell and T lymphocyte function and
their ability to kill, miRNAs have also been shown to
change the cell surface ligands on tumor cells to allow for
immune evasion from the NK cell receptor NKG2D. In
both human breast cancer stem cells and ovarian cancer,
overexpression of miR-20a has been shown to promote im-
mune evasion from NK cells through decreased transcrip-
tion of MICA/B proteins, the ligand of the NKG2D
receptor on NK and cytotoxic T-cells [97, 98]. Similarly
miR-10b directly binds MICB and downregulates its mem-
brane expression, decreasing NKG2D-mediated tumor
killing [99]. Contradicting these findings, miR-17/20a over-
expression has also been shown to be a tumor suppressor
by enhancing NK-cell detection via Mekk2-Mek5-Erk5
pathway in breast and colon primary tumors [100]. More-
over, miRNAs can change the expression of NKG2D
immunoreceptor ligands inhibiting NK and T cell tumor
killing as seen in miR-29 downregulation in many solid
tumor lines causing upregulation of B7-H3 expression and
miR-34a/c upregulation decreasing ULBP2 expression
[101, 102]. Further studies are warranted to clarify the role
of the miR-17-92 cluster and other miRNAs in the NK-
mediated immunologic response within the TME.
Conclusions and future directions
As has been shown throughout this review, miRNAs
have an important and varied effect on human carcino-
genesis by shaping the biology of the TME towards a
more permissive pro-tumoral phenotype. The complex
events leading to such an outcome are currently quite
universally defined as the “educational” process of cancer
cells on the surrounding TME. While the initial focus
was on the direction from the cancer cell to the sur-
rounding TME, increasingly interest is centered on the
implications of a more dynamic bidirectional exchange
of genetic information. MiRNAs represent only part of
the cargo of the extracellular vesicles, but an increasing
scientific literature points towards their pivotal role in
creating the micro-environmental conditions for cancer
cell growth and dissemination. The nearby future will
have to address several questions still unanswered. First,
it is absolutely necessary to clarify which miRNAs and
to what extent they are involved in this process. The
contradictory results of some studies can be explained
by the differences in tumor-types and by different
concentrations of miRNAs used for functional studies.
Understanding whether different concentrations of the
same miRNA elicit different target effects and therefore
changes the biology of the TME, will represent a signifi-
cant consideration in the development of this field. It is
certainly very attractive (especially in an attempt to
develop new and desperately needed better cancer bio-
markers) to think that concentrations of miRNAs within
the TME are reflected systemically in the circulating
levels of that same miRNA, however this has not yet
been irrefutably demonstrated. Moreover, the study of
the paracrine interactions among different cell popula-
tions of the TME and their reciprocal effects has been
limited to two, maximum three cell populations. This is
still way too far from describing the complexity of the
TME and only the development of new tridimensional
models of the TME will be able to cast a more conclu-
sive light on such complexity. Finally, the pharmacokin-
etics of miRNA-containing vesicles is in its infancy at
best, and needs to be further developed if the goal is
development of new therapies based on the use of
exosomic miRNAs. Therefore, the future of miRNA re-
search, particularly in its role in the TME, holds still a
lot of questions that need answering. However, for these
exact same reasons, this is an incredibly exciting time
for research in this field. We can envision a not too far
future in which these concerns will be satisfactorily
addressed and our understanding of the role of miRNAs
within the TME will allow us to use them as new thera-
peutic weapons to successfully improve the clinical out-
come of cancer patients.
Acknowledgments
Dr. Fabbri is a St. Baldrick Foundation’s Scholar and is supported by the
Concern Foundation, a Hyundai Hope on Wheels grant, a William Lawrence
& Blanche Hughes Foundation grant, a Jean Perkins Foundation grant, the
Nautica Malibu Triathlon Funds, a STOP Cancer grant, the Hugh and Audy
Lou Colvin Foundation grant, an Alex’s Lemonade Stand Foundation grant,
and the award number P30CA014089 from the National Cancer Institute.
Authors’ contributions
Both authors were involved in drafting the manuscript, revising it for
intellectual content, and reading and approving the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Author details
1Children’s Center for Cancer and Blood Diseases and The Saban Research
Institute, Children’s Hospital, Los Angeles, Los Angeles, CA, USA.
2Departments of Pediatrics and Molecular Microbiology & Immunology,
Norris Comprehensive Cancer Center, Keck School of Medicine, University of
Southern California, Los Angeles, CA, USA. 34650 Sunset Blvd MS #57, Los
Angeles, CA 90027, USA.
Received: 19 February 2016 Accepted: 12 May 2016
Frediani and Fabbri Molecular Cancer  (2016) 15:42 Page 7 of 11
References
1. Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and
friends. J Cell Biol. 2013;200(4):373–83. doi:10.1083/jcb.201211138. PubMed
PMID: 23420871; PMCID: PMC3575529.
2. Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation:
microRNAs can up-regulate translation. Science. 2007;318(5858):1931–4.
doi:10.1126/science.1149460.
3. Ambros V, Lee RC, Lavanway A, Williams PT, Jewell D. MicroRNAs and other
tiny endogenous RNAs in C. elegans. Curr Biol. 2003;13(10):807–18.
4. Lin SL, Miller JD, Ying SY. Intronic microRNA (miRNA). J Biomed Biotechnol.
2006;2006(4):26818. doi:10.1155/JBB/2006/26818. PubMed PMID: 17057362;
PMCID: PMC1559912.
5. Ling H, Fabbri M, Calin GA. MicroRNAs and other non-coding RNAs as targets
for anticancer drug development. Nat Rev Drug Discov. 2013;12(11):847–65.
doi:10.1038/nrd4140.
6. Fabbri M. Non-coding RNAs and cancer. New York: Springer; 2014.
7. Umezu T, Ohyashiki K, Kuroda M, Ohyashiki JH. Leukemia cell to endothelial
cell communication via exosomal miRNAs. Oncogene. 2013;32(22):2747–55.
doi:10.1038/onc.2012.295.
8. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio
M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A,
Vecchione A, Negrini M, Harris CC, Croce CM. A microRNA expression
signature of human solid tumors defines cancer gene targets. Proc Natl
Acad Sci U S A. 2006;103(7):2257–61. doi:10.1073/pnas.0510565103. PubMed
PMID: 16461460; PMCID: PMC1413718.
9. Yamada N, Tsujimura N, Kumazaki M, Shinohara H, Taniguchi K, Nakagawa Y,
Naoe T, Akao Y. Colorectal cancer cell-derived microvesicles containing
microRNA-1246 promote angiogenesis by activating Smad 1/5/8 signaling
elicited by PML down-regulation in endothelial cells. Biochim Biophys Acta.
2014;1839(11):1256–72. doi:10.1016/j.bbagrm.2014.09.002.
10. Mao G, Liu Y, Fang X, Fang L, Lin L, Liu X, Wang N. Tumor-derived
microRNA-494 promotes angiogenesis in non-small cell lung cancer.
Angiogenesis. 2015;18(3):373–82. doi:10.1007/s10456-015-9474-5.
11. Umezu T, Tadokoro H, Azuma K, Yoshizawa S, Ohyashiki K, Ohyashiki JH.
Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances
angiogenesis by targeting factor-inhibiting HIF-1. Blood. 2014;124(25):
3748–57. doi:10.1182/blood-2014-05-576116. PubMed PMID: 25320245;
PMCID: PMC4263983.
12. Zhuang G, Wu X, Jiang Z, Kasman I, Yao J, Guan Y, Oeh J, Modrusan Z, Bais
C, Sampath D, Ferrara N. Tumour-secreted miR-9 promotes endothelial cell
migration and angiogenesis by activating the JAK-STAT pathway. EMBO J.
2012;31(17):3513–23. doi:10.1038/emboj.2012.183. PubMed PMID: 22773185;
PMCID: PMC3433782.
13. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, Teruya-Feldstein J,
Reinhardt F, Onder TT, Valastyan S, Westermann F, Speleman F,
Vandesompele J, Weinberg RA. miR-9, a MYC/MYCN-activated microRNA,
regulates E-cadherin and cancer metastasis. Nat Cell Biol. 2010;12(3):247–56.
doi:10.1038/ncb2024. PubMed PMID: 20173740; PMCID: PMC2845545.
14. Saito K, Kondo E, Matsushita M. MicroRNA 130 family regulates the hypoxia
response signal through the P-body protein DDX6. Nucleic Acids Res. 2011;
39(14):6086–99. doi:10.1093/nar/gkr194. PubMed PMID: 21486751; PMCID:
PMC3152344.
15. Lei Z, Li B, Yang Z, Fang H, Zhang GM, Feng ZH, Huang B. Regulation of
HIF-1alpha and VEGF by miR-20b tunes tumor cells to adapt to the
alteration of oxygen concentration. PLoS One. 2009;4(10):e7629. doi:10.1371/
journal.pone.0007629. PubMed PMID: 19893619; PMCID: PMC2764090.
16. Wu Z, Cai X, Huang C, Xu J, Liu A. miR-497 suppresses angiogenesis in
breast carcinoma by targeting HIF-1α. Oncol Rep. 2015. doi: 10.3892/or.
2015.4529.
17. Yan JJ, Zhang YN, Liao JZ, Ke KP, Chang Y, Li PY, Wang M, Lin JS, He XX.
MiR-497 suppresses angiogenesis and metastasis of hepatocellular
carcinoma by inhibiting VEGFA and AEG-1. Oncotarget. 2015;6(30):
29527–42. doi:10.18632/oncotarget.5012.
18. Zhang Z, Zhang Y, Sun XX, Ma X, Chen ZN. microRNA-146a inhibits cancer
metastasis by downregulating VEGF through dual pathways in hepatocellular
carcinoma. Mol Cancer. 2015;14:5. doi:10.1186/1476-4598-14-5. PubMed PMID:
25608619; PMCID: PMC4326400.
19. Ho AS, Huang X, Cao H, Christman-Skieller C, Bennewith K, Le QT, Koong
AC. Circulating miR-210 as a Novel Hypoxia Marker in Pancreatic Cancer.
Transl Oncol. 2010;3(2):109–13. PubMed PMID: 20360935; PMCID:
PMC2847318.
20. Camps C, Buffa FM, Colella S, Moore J, Sotiriou C, Sheldon H, Harris AL,
Gleadle JM, Ragoussis J. hsa-miR-210 Is induced by hypoxia and is an
independent prognostic factor in breast cancer. Clin Cancer Res. 2008;14(5):
1340–8. doi:10.1158/1078-0432.CCR-07-1755.
21. Ghosh G, Subramanian IV, Adhikari N, Zhang X, Joshi HP, Basi D,
Chandrashekhar YS, Hall JL, Roy S, Zeng Y, Ramakrishnan S. Hypoxia-
induced microRNA-424 expression in human endothelial cells regulates HIF-
α isoforms and promotes angiogenesis. J Clin Invest. 2010;120(11):4141–54.
doi:10.1172/JCI42980. PubMed PMID: 20972335; PMCID: PMC2964978.
22. Bovy N, Blomme B, Frères P, Dederen S, Nivelles O, Lion M, Carnet O, Martial
JA, Noël A, Thiry M, Jérusalem G, Josse C, Bours V, Tabruyn SP, Struman I.
Endothelial exosomes contribute to the antitumor response during
breast cancer neoadjuvant chemotherapy via microRNA transfer.
Oncotarget. 2015;6(12):10253–66. doi:10.18632/oncotarget.3520. PubMed
PMID: 25860935; PMCID: PMC4496353.
23. Pecot CV, Rupaimoole R, Yang D, Akbani R, Ivan C, Lu C, Wu S, Han HD,
Shah MY, Rodriguez-Aguayo C, Bottsford-Miller J, Liu Y, Kim SB, Unruh A,
Gonzalez-Villasana V, Huang L, Zand B, Moreno-Smith M, Mangala LS, Taylor
M, Dalton HJ, Sehgal V, Wen Y, Kang Y, Baggerly KA, Lee JS, Ram PT, Ravoori
MK, Kundra V, Zhang X, Ali-Fehmi R, Gonzalez-Angulo AM, Massion PP, Calin
GA, Lopez-Berestein G, Zhang W, Sood AK. Tumour angiogenesis regulation
by the miR-200 family. Nat Commun. 2013;4:2427. doi:10.1038/ncomms3427.
PubMed PMID: 24018975; PMCID: PMC3904438.
24. Siragam V, Rutnam ZJ, Yang W, Fang L, Luo L, Yang X, Li M, Deng Z, Qian J,
Peng C, Yang BB. MicroRNA miR-98 inhibits tumor angiogenesis and
invasion by targeting activin receptor-like kinase-4 and matrix
metalloproteinase-11. Oncotarget. 2012;3(11):1370–85. PubMed PMID:
23211491; PMCID: PMC3717799.
25. Lu Z, Zhang W, Gao S, Jiang Q, Xiao Z, Ye L, Zhang X. MiR-506 suppresses
liver cancer angiogenesis through targeting sphingosine kinase 1
(SPHK1) mRNA. Biochem Biophys Res Commun. 2015;468(1–2):8–13. doi:
10.1016/j.bbrc.2015.11.008.
26. Png KJ, Halberg N, Yoshida M, Tavazoie SF. A microRNA regulon that mediates
endothelial recruitment and metastasis by cancer cells. Nature. 2012;481(7380):
190–4. doi:10.1038/nature10661.
27. Jusufović E, Rijavec M, Keser D, Korošec P, Sodja E, Iljazović E, Radojević Z,
Košnik M. let-7b and miR-126 are down-regulated in tumor tissue and
correlate with microvessel density and survival outcomes in non–small–cell
lung cancer. PLoS One. 2012;7(9):e45577. doi:10.1371/journal.pone.0045577.
PubMed PMID: 23029111; PMCID: PMC3454421.
28. He T, Qi F, Jia L, Wang S, Song N, Guo L, Fu Y, Luo Y. MicroRNA-542-3p
inhibits tumour angiogenesis by targeting angiopoietin-2. J Pathol. 2014;
232(5):499–508. doi:10.1002/path.4324.
29. Vong S, Kalluri R. The role of stromal myofibroblast and extracellular matrix
in tumor angiogenesis. Genes Cancer. 2011;2(12):1139–45. doi:10.1177/
1947601911423940. PubMed PMID: 22866205; PMCID: PMC3411128.
30. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006;6(5):392–401.
doi:10.1038/nrc1877.
31. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition.
J Clin Invest. 2009;119(6):1420–8. doi:10.1172/JCI39104. PubMed PMID:
19487818; PMCID: PMC2689101.
32. Mitra AK, Zillhardt M, Hua Y, Tiwari P, Murmann AE, Peter ME, Lengyel E.
MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts
in ovarian cancer. Cancer Discov. 2012;2(12):1100–8. doi:10.1158/2159-8290.
CD-12-0206. PubMed PMID: 23171795; PMCID: PMC3685866.
33. Aprelikova O, Yu X, Palla J, Wei BR, John S, Yi M, Stephens R, Simpson RM,
Risinger JI, Jazaeri A, Niederhuber J. The role of miR-31 and its target gene
SATB2 in cancer-associated fibroblasts. Cell Cycle. 2010;9(21):4387–98.
PubMed PMID: 20980827; PMCID: PMC3055190.
34. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL,
Polyak K, Tubo R, Weinberg RA. Mesenchymal stem cells within tumour
stroma promote breast cancer metastasis. Nature. 2007;449(7162):557–63.
doi:10.1038/nature06188.
35. Long H, Xie R, Xiang T, Zhao Z, Lin S, Liang Z, Chen Z, Zhu B. Autocrine
CCL5 signaling promotes invasion and migration of CD133+ ovarian cancer
stem-like cells via NF-κB-mediated MMP-9 upregulation. Stem Cells. 2012;
30(10):2309–19. doi:10.1002/stem.1194.
36. Zhang Y, Lv D, Kim HJ, Kurt RA, Bu W, Li Y, Ma X. A novel role of hematopoietic
CCL5 in promoting triple-negative mammary tumor progression by regulating
generation of myeloid-derived suppressor cells. Cell Res. 2013;23(3):394–408.
doi:10.1038/cr.2012.178. PubMed PMID: 23266888; PMCID: PMC3587709.
Frediani and Fabbri Molecular Cancer  (2016) 15:42 Page 8 of 11
37. Taddei ML, Cavallini L, Comito G, Giannoni E, Folini M, Marini A, Gandellini
P, Morandi A, Pintus G, Raspollini MR, Zaffaroni N, Chiarugi P. Senescent
stroma promotes prostate cancer progression: the role of miR-210. Mol
Oncol. 2014;8(8):1729–46. doi:10.1016/j.molonc.2014.07.009.
38. Doldi V, Callari M, Giannoni E, D’Aiuto F, Maffezzini M, Valdagni R, Chiarugi
P, Gandellini P, Zaffaroni N. Integrated gene and miRNA expression analysis
of prostate cancer associated fibroblasts supports a prominent role for
interleukin-6 in fibroblast activation. Oncotarget. 2015;6(31):31441–60. doi:10.
18632/oncotarget.5056.
39. Li P, Shan JX, Chen XH, Zhang D, Su LP, Huang XY, Yu BQ, Zhi QM, Li CL,
Wang YQ, Tomei S, Cai Q, Ji J, Li JF, Chouchane L, Yu YY, Sun FZ, Xu ZH, Liu
BY, Zhu ZG. Epigenetic silencing of microRNA-149 in cancer-associated
fibroblasts mediates prostaglandin E2/interleukin-6 signaling in the tumor
microenvironment. Cell Res. 2015;25(5):588–603. doi:10.1038/cr.2015.51.
PubMed PMID: 25916550; PMCID: PMC4423088.
40. Josson S, Gururajan M, Sung SY, Hu P, Shao C, Zhau HE, Liu C, Lichterman J,
Duan P, Li Q, Rogatko A, Posadas EM, Haga CL, Chung LW. Stromal fibroblast-
derived miR-409 promotes epithelial-to-mesenchymal transition and prostate
tumorigenesis. Oncogene. 2015;34(21):2690–9. doi:10.1038/onc.2014.212.
41. Le MT, Hamar P, Guo C, Basar E, Perdigão-Henriques R, Balaj L, Lieberman J.
miR-200-containing extracellular vesicles promote breast cancer cell
metastasis.
J Clin Invest. 2014;124(12):5109–28. doi:10.1172/JCI75695. PubMed PMID:
25401471; PMCID: PMC4348969.
42. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation
and progression. Nature. 2004;432(7015):332–7. doi:10.1038/nature03096.
PubMed PMID: 15549095; PMCID: PMC3050735.
43. Musumeci M, Coppola V, Addario A, Patrizii M, Maugeri-Saccà M, Memeo L,
Colarossi C, Francescangeli F, Biffoni M, Collura D, Giacobbe A, D’Urso L,
Falchi M, Venneri MA, Muto G, De Maria R, Bonci D. Control of tumor and
microenvironment cross-talk by miR-15a and miR-16 in prostate cancer.
Oncogene. 2011;30(41):4231–42. doi:10.1038/onc.2011.140.
44. Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L, D’Urso
L, Pagliuca A, Biffoni M, Labbaye C, Bartucci M, Muto G, Peschle C, De Maria
R. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting
multiple oncogenic activities. Nat Med. 2008;14(11):1271–7. doi:10.1038/nm.
1880.
45. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE,
Aqeilan RI, Zupo S, Dono M, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ,
Negrini M, Croce CM. miR-15 and miR-16 induce apoptosis by targeting
BCL2. Proc Natl Acad Sci U S A. 2005;102(39):13944–9. doi:10.1073/pnas.
0506654102. PubMed PMID: 16166262; PMCID: PMC1236577.
46. Calin GA, Cimmino A, Fabbri M, Ferracin M, Wojcik SE, Shimizu M, Taccioli C,
Zanesi N, Garzon R, Aqeilan RI, Alder H, Volinia S, Rassenti L, Liu X, Liu CG,
Kipps TJ, Negrini M, Croce CM. MiR-15a and miR-16-1 cluster functions in
human leukemia. Proc Natl Acad Sci U S A. 2008;105(13):5166–71. doi:10.
1073/pnas.0800121105. PubMed PMID: 18362358; PMCID: PMC2278188.
47. Aprelikova O, Palla J, Hibler B, Yu X, Greer YE, Yi M, Stephens R, Maxwell GL,
Jazaeri A, Risinger JI, Rubin JS, Niederhuber J. Silencing of miR-148a in
cancer-associated fibroblasts results in WNT10B-mediated stimulation of
tumor cell motility. Oncogene. 2013;32(27):3246–53. doi:10.1038/onc.2012.
351. PubMed PMID: 22890324; PMCID: PMC3711253.
48. Olson P, Lu J, Zhang H, Shai A, Chun MG, Wang Y, Libutti SK, Nakakura EK,
Golub TR, Hanahan D. MicroRNA dynamics
in the stages of tumorigenesis correlate with hallmark capabilities of cancer.
Genes Dev. 2009;23(18):2152–65. doi:10.1101/gad.1820109. PubMed PMID:
19759263; PMCID: PMC2751988.
49. Nouraee N, Van Roosbroeck K, Vasei M, Semnani S, Samaei NM, Naghshvar
F, Omidi AA, Calin GA, Mowla SJ. Expression, tissue distribution and function
of miR-21 in esophageal squamous cell carcinoma. PLoS One. 2013;8(9):
e73009. doi:10.1371/journal.pone.0073009. PubMed PMID: 24039846; PMCID:
PMC3769386.
50. Zhang J, Liu J, Liu Y, Wu W, Li X, Wu Y, Chen H, Zhang K, Gu L. miR-101
represses lung cancer by inhibiting interaction of fibroblasts and cancer
cells by down-regulating CXCL12. Biomed Pharmacother. 2015;74:215–21.
doi:10.1016/j.biopha.2015.08.013.
51. Bronisz A, Godlewski J, Wallace JA, Merchant AS, Nowicki MO, Mathsyaraja
H, Srinivasan R, Trimboli AJ, Martin CK, Li F, Yu L, Fernandez SA, Pécot T,
Rosol TJ, Cory S, Hallett M, Park M, Piper MG, Marsh CB, Yee LD, Jimenez RE,
Nuovo G, Lawler SE, Chiocca EA, Leone G, Ostrowski MC. Reprogramming of
the tumour microenvironment by stromal PTEN-regulated miR-320. Nat Cell
Biol. 2012;14(2):159–67. doi:10.1038/ncb2396. PubMed PMID: 22179046;
PMCID: PMC3271169.
52. Zhang Y, Yang P, Sun T, Li D, Xu X, Rui Y, Li C, Chong M, Ibrahim T,
Mercatali L, Amadori D, Lu X, Xie D, Li QJ, Wang XF. miR-126 and miR-126*
repress recruitment of mesenchymal stem cells and inflammatory
monocytes to inhibit breast cancer metastasis. Nat Cell Biol. 2013;15(3):284–
94. doi:10.1038/ncb2690. PubMed PMID: 23396050; PMCID: PMC3672398.
53. Farahani M, Rubbi C, Liu L, Slupsky JR, Kalakonda N. CLL Exosomes Modulate
the Transcriptome and Behaviour of Recipient Stromal Cells and Are Selectively
Enriched in miR-202-3p. PLoS One. 2015;10(10):e0141429. doi:10.1371/journal.
pone.0141429. PubMed PMID: 26509439; PMCID: PMC4625016.
54. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the
tumor microenvironment. Cell. 2010;141(1):52–67. doi:10.1016/j.cell.2010.03.
015. PubMed PMID: 20371345; PMCID: PMC2862057.
55. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-
21 regulates expression of the PTEN tumor suppressor gene in human
hepatocellular cancer. Gastroenterology. 2007;133(2):647–58. doi:10.1053/j.
gastro.2007.05.022.
56. Wang Q, Tang H, Yin S, Dong C. Downregulation of microRNA-138
enhances the proliferation, migration and invasion of cholangiocarcinoma
cells through the upregulation of RhoC/p-ERK/MMP-2/MMP-9. Oncol Rep.
2013;29(5):2046–52. doi:10.3892/or.2013.2304.
57. Chou J, Lin JH, Brenot A, Kim JW, Provot S, Werb Z. GATA3 suppresses
metastasis and modulates the tumour microenvironment by regulating
microRNA-29b expression. Nat Cell Biol. 2013;15(2):201–13. doi:10.1038/
ncb2672. PubMed PMID: 23354167; PMCID: PMC3660859.
58. Song N, Liu H, Ma X, Zhang S. Placental growth factor promotes metastases
of ovarian cancer through MiR-543-regulated MMP7. Cell Physiol Biochem.
2015;37(3):1104–12. doi:10.1159/000430235.
59. Du WW, Fang L, Li M, Yang X, Liang Y, Peng C, Qian W, O’Malley YQ,
Askeland RW, Sugg SL, Qian J, Lin J, Jiang Z, Yee AJ, Sefton M, Deng Z,
Shan SW, Wang CH, Yang BB. MicroRNA miR-24 enhances tumor invasion
and metastasis by targeting PTPN9 and PTPRF to promote EGF signaling. J
Cell Sci. 2013;126(Pt 6):1440–53. doi:10.1242/jcs.118299.
60. Gabriely G, Wurdinger T, Kesari S, Esau CC, Burchard J, Linsley PS, Krichevsky
AM. MicroRNA 21 promotes glioma invasion by targeting matrix
metalloproteinase regulators. Mol Cell Biol. 2008;28(17):5369–80. doi:10.
1128/MCB.00479-08. PubMed PMID: 18591254; PMCID: PMC2519720.
61. Fang L, Deng Z, Shatseva T, Yang J, Peng C, Du WW, Yee AJ, Ang LC, He C,
Shan SW, Yang BB. MicroRNA miR-93 promotes tumor growth and
angiogenesis by targeting integrin-β8. Oncogene. 2011;30(7):806–21. doi:10.
1038/onc.2010.465.
62. Hunt S, Jones AV, Hinsley EE, Whawell SA, Lambert DW. MicroRNA-124
suppresses oral squamous cell carcinoma motility by targeting ITGB1. FEBS
Lett. 2011;585(1):187–92. doi:10.1016/j.febslet.2010.11.038.
63. Li G, Luna C, Qiu J, Epstein DL, Gonzalez P. Targeting of integrin beta1 and
kinesin 2alpha by microRNA 183. J Biol Chem. 2010;285(8):5461–71. doi:10.
1074/jbc.M109.037127. PubMed PMID: 19940135; PMCID: PMC2820774.
64. Shan SW, Lee DY, Deng Z, Shatseva T, Jeyapalan Z, Du WW, Zhang Y, Xuan
JW, Yee SP, Siragam V, Yang BB. MicroRNA MiR-17 retards tissue growth and
represses fibronectin expression. Nat Cell Biol. 2009;11(8):1031–8. doi:10.
1038/ncb1917.
65. Ji J, Zhao L, Budhu A, Forgues M, Jia HL, Qin LX, Ye QH, Yu J, Shi X, Tang
ZY, Wang XW. Let-7g targets collagen type I alpha2 and inhibits cell
migration in hepatocellular carcinoma. J Hepatol. 2010;52(5):690–7. doi:10.
1016/j.jhep.2009.12.025. PubMed PMID: 20338660; PMCID: PMC2862772.
66. Su B, Zhao W, Shi B, Zhang Z, Yu X, Xie F, Guo Z, Zhang X, Liu J, Shen Q,
Wang J, Li X, Zhou L. Let-7d suppresses growth, metastasis, and tumor
macrophage infiltration in renal cell carcinoma by targeting COL3A1 and
CCL7. Mol Cancer. 2014;13:206. doi:10.1186/1476-4598-13-206. PubMed
PMID: 25193015; PMCID: PMC4168121.
67. Verghese ET, Drury R, Green CA, Holliday DL, Lu X, Nash C, Speirs V, Thorne
JL, Thygesen HH, Zougman A, Hull MA, Hanby AM, Hughes TA. MiR-26b is
down-regulated in carcinoma-associated fibroblasts from ER-positive breast
cancers leading to enhanced cell migration and invasion. J Pathol. 2013;
231(3):388–99. doi:10.1002/path.4248. PubMed PMID: 23939832; PMCID:
PMC4030585.
68. Zhou W, Fong MY, Min Y, Somlo G, Liu L, Palomares MR, Yu Y, Chow A,
O’Connor ST, Chin AR, Yen Y, Wang Y, Marcusson EG, Chu P, Wu J, Wu X, Li
AX, Li Z, Gao H, Ren X, Boldin MP, Lin PC, Wang SE. Cancer-secreted miR-
105 destroys vascular endothelial barriers to promote metastasis. Cancer
Frediani and Fabbri Molecular Cancer  (2016) 15:42 Page 9 of 11
Cell. 2014;25(4):501–15. doi:10.1016/j.ccr.2014.03.007. PubMed PMID:
24735924; PMCID: PMC4016197.
69. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell.
2011;144(5):646–74. doi:10.1016/j.cell.2011.02.013.
70. Asgharzadeh S, Salo JA, Ji L, Oberthuer A, Fischer M, Berthold F, Hadjidaniel
M, Liu CW, Metelitsa LS, Pique-Regi R, Wakamatsu P, Villablanca JG,
Kreissman SG, Matthay KK, Shimada H, London WB, Sposto R, Seeger RC.
Clinical significance of tumor-associated inflammatory cells in metastatic
neuroblastoma. J Clin Oncol. 2012;30(28):3525–32. doi:10.1200/JCO.2011.40.
9169. PubMed PMID: 22927533; PMCID: 3675667.
71. Zhang QW, Liu L, Gong CY, Shi HS, Zeng YH, Wang XZ, Zhao YW, Wei YQ.
Prognostic significance of tumor-associated macrophages in solid tumor: a
meta-analysis of the literature. PLoS One. 2012;7(12), e50946. doi:10.1371/
journal.pone.0050946. PubMed PMID: 23284651; PMCID: PMC3532403.
72. Jinushi M, Komohara Y. Tumor-associated macrophages as an emerging
target against tumors: Creating a new path from bench to bedside. Biochim
Biophys Acta. 2015;1855(2):123–30. doi:10.1016/j.bbcan.2015.01.002.
73. Colvin EK. Tumor-associated macrophages contribute to tumor progression
in ovarian cancer. Front Oncol. 2014;4:137. doi:10.3389/fonc.2014.00137.
PubMed PMID: 24936477; PMCID: PMC4047518.
74. Marelli G, Allavena P, Erreni M. Tumor-associated macrophages, multi-
tasking cells in the cancer landscape. Cancer Res Frontiers. 2015;1(2):149–61.
75. Fabbri M, Paone A, Calore F, Galli R, Gaudio E, Santhanam R, Lovat F, Fadda
P, Mao C, Nuovo GJ, Zanesi N, Crawford M, Ozer GH, Wernicke D, Alder H,
Caligiuri MA, Nana-Sinkam P, Perrotti D, Croce CM. MicroRNAs bind to Toll-
like receptors to induce prometastatic inflammatory response. Proc Natl
Acad Sci U S A. 2012;109(31):E2110–6. doi:10.1073/pnas.1209414109.
PubMed PMID: 22753494; PMCID: PMC3412003.
76. Challagundla KB, Wise PM, Neviani P, Chava H, Murtadha M, Xu T, Kennedy
R, Ivan C, Zhang X, Vannini I, Fanini F, Amadori D, Calin GA, Hadjidaniel M,
Shimada H, Jong A, Seeger RC, Asgharzadeh S, Goldkorn A, Fabbri M.
Exosome-Mediated Transfer of microRNAs Within the Tumor Microenvironment
and Neuroblastoma Resistance to Chemotherapy. J Natl Cancer Inst. 2015;107(7).
doi: 10.1093/jnci/djv135.
77. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E,
Pedriali M, Fabbri M, Campiglio M, Ménard S, Palazzo JP, Rosenberg A,
Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM.
MicroRNA gene expression deregulation in human breast cancer. Cancer
Res. 2005;65(16):7065–70. doi:10.1158/0008-5472.CAN-05-1783.
78. Stenvold H, Donnem T, Andersen S, Al-Saad S, Valkov A, Pedersen MI,
Busund LT, Bremnes RM. High tumor cell expression of microRNA-21 in
node positive non-small cell lung cancer predicts a favorable clinical
outcome. BMC Clin Pathol. 2014;14(1):9. doi:10.1186/1472-6890-14-9.
PubMed PMID: 24524655; PMCID: PMC3931486.
79. Gao J, Zhang Q, Xu J, Guo L, Li X. Clinical significance of serum miR-21 in
breast cancer compared with CA153 and CEA. Chin J Cancer Res. 2013;25(6):
743–8. doi:10.3978/j.issn.1000-9604.2013.12.04. PubMed PMID: 24385703;
PMCID: PMC3872537.
80. Wang G, Wang L, Sun S, Wu J, Wang Q. Quantitative measurement of serum
microRNA-21 expression in relation to breast cancer metastasis in Chinese
females. Ann Lab Med. 2015;35(2):226–32. doi:10.3343/alm.2015.35.2.226.
PubMed PMID: 25729725; PMCID: PMC4330173.
81. Toiyama Y, Takahashi M, Hur K, Nagasaka T, Tanaka K, Inoue Y, Kusunoki M,
Boland CR, Goel A. Serum miR-21 as a diagnostic and prognostic biomarker
in colorectal cancer. J Natl Cancer Inst. 2013;105(12):849–59. doi:10.1093/
jnci/djt101. PubMed PMID: 23704278; PMCID: PMC3687369.
82. Yang M, Chen J, Su F, Yu B, Lin L, Liu Y, Huang JD, Song E. Microvesicles
secreted by macrophages shuttle invasion-potentiating microRNAs into
breast cancer cells. Mol Cancer. 2011;10:117. doi:10.1186/1476-4598-10-117.
PubMed PMID: 21939504; PMCID: PMC3190352.
83. Lin X, Chen L, Yao Y, Zhao R, Cui X, Chen J, Hou K, Zhang M, Su F, Song E.
CCL18-mediated down-regulation of miR98 and miR27b promotes breast
cancer metastasis. Oncotarget. 2015;6(24):20485–99. doi:10.18632/
oncotarget.4107. PubMed PMID: 26244871; PMCID: PMC4653020.
84. Nilsson S, Möller C, Jirström K, Lee A, Busch S, Lamb R, Landberg G.
Downregulation of miR-92a is associated with aggressive breast cancer
features and increased tumour macrophage infiltration. PLoS One. 2012;7(4),
e36051. doi:10.1371/journal.pone.0036051. PubMed PMID: 22563438; PMCID:
PMC3338574.
85. Xu S, Wei J, Wang F, Kong LY, Ling XY, Nduom E, Gabrusiewicz K, Doucette T,
Yang Y, Yaghi NK, Fajt V, Levine JM, Qiao W, Li XG, Lang FF, Rao G, Fuller GN,
Calin GA, Heimberger AB. Effect of miR-142-3p on the M2 macrophage and
therapeutic efficacy against murine glioblastoma. J Natl Cancer Inst. 2014;
106(8). doi: 10.1093/jnci/dju162. PubMed PMID: 24974128; PMCID:
PMC4271080.
86. Xu Z, Zhao L, Zhu LY, He M, Zheng L, Wu Y. MicroRNA-17, 20a regulates the
proangiogenic function of tumor-associated macrophages via targeting
hypoxia-inducible factor 2α. PLoS One. 2013;8(10), e77890. doi:10.1371/
journal.pone.0077890. PubMed PMID: 24194900; PMCID: PMC3806827.
87. Li Y, Zhao L, Shi B, Ma S, Xu Z, Ge Y, Liu Y, Zheng D, Shi J. Functions of miR-
146a and miR-222 in Tumor-associated Macrophages in Breast Cancer. Sci
Rep. 2015;5:18648.
doi:10.1038/srep18648. PubMed PMID: 26689540; PMCID: PMC4686897.
88. Chaudhuri AA, So AY, Sinha N, Gibson WS, Taganov KD, O’Connell RM,
Baltimore D. MicroRNA-125b potentiates macrophage activation. J Immunol.
2011;187(10):5062–8. doi:10.4049/jimmunol.1102001. PubMed PMID:
22003200; PMCID: PMC3208133.
89. Ma S, Liu M, Xu Z, Li Y, Guo H, Ge Y, Liu Y, Zheng D, Shi J. A double feedback
loop mediated by microRNA-23a/27a/24-2 regulates M1 versus M2 macrophage
polarization and thus regulates cancer progression. Oncotarget. 2015. doi: 10.
18632/oncotarget.6284
90. Squadrito ML, Pucci F, Magri L, Moi D, Gilfillan GD, Ranghetti A, Casazza A,
Mazzone M, Lyle R, Naldini L, De Palma M. miR-511-3p modulates genetic
programs of tumor-associated macrophages.
Cell Rep. 2012;1(2):141–54. doi:10.1016/j.celrep.2011.12.005.
91. Donatelli SS, Zhou JM, Gilvary DL, Eksioglu EA, Chen X, Cress WD, Haura EB,
Schabath MB, Coppola D, Wei S, Djeu JY. TGF-β-inducible microRNA-183
silences tumor-associated natural killer cells. Proc Natl Acad Sci U S A. 2014;
111(11):4203–8. doi:10.1073/pnas.1319269111. PubMed PMID: 24586048;
PMCID: PMC3964044.
92. Sun X, Zhang J, Hou Z, Han Q, Zhang C, Tian Z. miR-146a is directly regulated
by STAT3 in human hepatocellular carcinoma cells and involved in anti-tumor
immune suppression. Cell Cycle. 2015;14(2):243–52. doi:10.4161/15384101.2014.
977112. PubMed PMID: 25607648; PMCID: PMC4352959.
93. Tang B, Wu W, Wei X, Li Y, Ren G, Fan W. Activation of glioma cells generates
immune tolerant NKT cells. J Biol Chem. 2014;289(50):34595–600. doi:10.1074/
jbc.M114.614503. PubMed PMID: 25342742; PMCID: PMC4263866.
94. Noman MZ, Janji B, Berchem G, Chouaib S. miR-210 and hypoxic microvesicles:
Two critical components of hypoxia involved in the regulation of killer cells
function. Cancer Lett. 2015. doi: 10.1016/j.canlet.2015.10.026.
95. Berchem G, Noman MZ, Bosseler M, Paggetti J, Baconnais S, Lecam E,
Nanbakhsh A, Moussay E, Chouaib FM, Janji B, Chouaib S. Hypoxic tumor-
derived microvesicles negatively regulate NK cell function by a mechanism
involving TGF-beta and miR23a transfer. Onco Immunology 2015;5(4):
e1062968.
96. Yin Y, Cai X, Chen X, Liang H, Zhang Y, Li J, Wang Z, Zhang W,
Yokoyama S, Wang C, Li L, Hou D, Dong L, Xu T, Hiroi T, Yang F, Ji H,
Zhang J, Zen K, Zhang CY. Tumor-secreted miR-214 induces regulatory
T cells: a major link between immune evasion and tumor growth. Cell
Res. 2014;24(10):1164–80. doi:10.1038/cr.2014.121. PubMed PMID:
25223704; PMCID: PMC4185347.
97. Wang B, Wang Q, Wang Z, Jiang J, Yu SC, Ping YF, Yang J, Xu SL, Ye XZ, Xu
C, Yang L, Qian C, Wang JM, Cui YH, Zhang X, Bian XW. Metastatic
consequences of immune escape from NK cell cytotoxicity by human
breast cancer stem cells. Cancer Res. 2014;74(20):5746–57. doi:10.1158/0008-
5472.CAN-13-2563.
98. Xie J, Liu M, Li Y, Nie Y, Mi Q, Zhao S. Ovarian tumor-associated microRNA-
20a decreases natural killer cell cytotoxicity by downregulating MICA/B
expression. Cell Mol Immunol. 2014;11(5):495–502. doi:10.1038/cmi.2014.30.
PubMed PMID: 24813230; PMCID: PMC4197204.
99. Tsukerman P, Stern-Ginossar N, Gur C, Glasner A, Nachmani D, Bauman Y,
Yamin R, Vitenshtein A, Stanietsky N, Bar-Mag T, Lankry D, Mandelboim O.
MiR-10b downregulates the stress-induced cell surface molecule MICB, a
critical ligand for cancer cell recognition by natural killer cells. Cancer Res.
2012;72(21):5463–72. doi:10.1158/0008-5472.CAN-11-2671.
100. Jiang H, Wang P, Li X, Wang Q, Deng ZB, Zhuang X, Mu J, Zhang L, Wang B,
Yan J, Miller D, Zhang HG. Restoration of miR17/20a in solid tumor cells
enhances the natural killer cell antitumor activity by targeting Mekk2.
Cancer Immunol Res. 2014;2(8):789–99. doi:10.1158/2326-6066.CIR-13-0162.
PubMed PMID: 24801835; PMCID: PMC4396632.
101. Xu H, Cheung IY, Guo HF, Cheung NK. MicroRNA miR-29 modulates expression
of immunoinhibitory molecule B7-H3: potential implications for immune based
Frediani and Fabbri Molecular Cancer  (2016) 15:42 Page 10 of 11
therapy of human solid tumors. Cancer Res. 2009;69(15):6275–81. doi:10.1158/
0008-5472.CAN-08-4517. PubMed PMID: 19584290; PMCID: PMC2719680.
102. Heinemann A, Zhao F, Pechlivanis S, Eberle J, Steinle A, Diederichs S,
Schadendorf D, Paschen A. Tumor suppressive microRNAs miR-34a/c control
cancer cell expression of ULBP2, a stress-induced ligand of the natural killer
cell receptor NKG2D. Cancer Res. 2012;72(2):460–71. doi:10.1158/0008-5472.
CAN-11-1977.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Frediani and Fabbri Molecular Cancer  (2016) 15:42 Page 11 of 11
